Tudor Investment Corp ET AL Cuts Position in QuidelOrtho Co. (NASDAQ:QDEL)

Tudor Investment Corp ET AL reduced its holdings in QuidelOrtho Co. (NASDAQ:QDEL - Free Report) by 45.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,683 shares of the company's stock after selling 99,688 shares during the period. Tudor Investment Corp ET AL owned approximately 0.18% of QuidelOrtho worth $5,376,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in shares of QuidelOrtho by 64.5% during the 3rd quarter. Principal Financial Group Inc. now owns 272,037 shares of the company's stock worth $12,405,000 after purchasing an additional 106,642 shares during the last quarter. Moody National Bank Trust Division lifted its position in QuidelOrtho by 126.5% during the fourth quarter. Moody National Bank Trust Division now owns 37,868 shares of the company's stock worth $1,687,000 after buying an additional 21,147 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in QuidelOrtho during the fourth quarter worth $433,000. Oak Thistle LLC purchased a new stake in QuidelOrtho in the 4th quarter valued at $301,000. Finally, Merit Financial Group LLC acquired a new stake in shares of QuidelOrtho in the 4th quarter worth $301,000. 99.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. StockNews.com lowered shares of QuidelOrtho from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. JPMorgan Chase & Co. cut their price target on shares of QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating for the company in a report on Monday, April 21st. UBS Group upped their price objective on QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a report on Thursday, February 13th. Finally, Royal Bank of Canada cut their target price on QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating for the company in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $46.83.

QuidelOrtho Trading Down 4.1 %

Shares of NASDAQ QDEL traded down $1.13 during trading on Tuesday, reaching $26.56. The stock had a trading volume of 300,316 shares, compared to its average volume of 1,009,099. The company has a market cap of $1.79 billion, a P/E ratio of -0.87 and a beta of 0.13. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22. The business's 50-day moving average price is $32.07 and its 200-day moving average price is $38.37. QuidelOrtho Co. has a fifty-two week low of $23.77 and a fifty-two week high of $49.45.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. On average, equities research analysts predict that QuidelOrtho Co. will post 2.3 EPS for the current fiscal year.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.